Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway

<div>Result of immunohistochemical analysis. (a, b) Immunohistochemical analysis showed that there were significant differences in the staining of CD4, CD8, Ki67, etc. between the control group and the combination group.</div>

Journal of Oncology

fig7

Figure 7

Figure 7: Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway 